Thomas W. Burns, CEO of Glaukos, Joins Avedro’s Board of Directors
WALTHAM, Mass.--(BUSINESS WIRE)--Jul 31, 2018--Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that Thomas W. Burns has been elected to its Board of Directors.
Mr. Burns has a proven track record of building successful medical device and pharmaceutical businesses and creating successful new markets in ophthalmology. Mr. Burns is President, Chief Executive Officer and a member of the Board of Directors at Glaukos Corporation, an ophthalmic medical technology company that pioneered the Micro-Invasive Glaucoma Surgery (MIGS) clinical and commercial class to transform the treatment of glaucoma. In his 16 years at Glaukos, Mr. Burns has led the company from a small startup to the completion of an initial public offering in June 2015 and beyond.
Mr. Burns has more than 25 years of direct ophthalmic management experience, including over 20 years of general management experience across a broad range of ophthalmic medical devices, ophthalmic pharmaceuticals, drug delivery technologies, and surgical products. Over his career, he has raised nearly $400M in private offerings and in the public markets. Prior to Glaukos, Mr. Burns led Eyetech Pharmaceuticals (acquired by OSI Pharmaceuticals) as President, Chief Operating Officer and as a Director. He is currently Chairman of Dose Medical Inc.
“Tom’s broad leadership experience in ophthalmology, specifically growing Glaukos from a small startup to a successful public company, will be of great value to Avedro, and we are pleased to welcome him as an independent board member,” said Reza Zadno, Ph.D., Chief Executive Officer of Avedro. “We look forward to leveraging Tom’s expertise as we continue to develop innovative products that improve the corneal health, visual acuity and quality of life of patients around the world.”
“Since FDA approval in 2016, the company has demonstrated excellent progress in securing insurance coverage for cross-linking and advancing its next generation epi-on product candidate in a Phase 3 trial,” said Mr. Burns. “I am delighted to be joining Avedro’s Board of Directors at this exciting time and look forward to contributing to this company’s rapid growth.”
Avedro is a privately held pharmaceutical and medical device company and the world leader in corneal remodeling. Our patented cross-linking technology, consisting of drug formulations and medical devices, are approved for sale in numerous countries around the globe. We continue to develop proprietary corneal remodeling products for the treatment of keratoconus, corneal ectasia and for refractive correction as an alternative to contacts and eyeglasses. Keratoconus and corneal ectasia are rare and sight-threatening eye conditions in which the cornea progressively thins and weakens causing the development of a cone-like bulge and optical irregularity of the cornea which can result in significant visual impairment. At Avedro, our mission is to produce and deliver innovative, minimally invasive drugs and devices for corneal remodeling to eyecare professionals around the world to improve patients’ vision and quality of life.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005048/en/
CONTACT: Avedro Contact:
David Iannetta, 781-768-3400
Gray Communications, LLC.
Michele Gray, 917-449-9250
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES OPTICAL PHARMACEUTICAL
SOURCE: Avedro, Inc.
Copyright Business Wire 2018.
PUB: 07/31/2018 08:00 AM/DISC: 07/31/2018 08:01 AM